Hui Zhou

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +13

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)

Yunpeng Yang, Zhehai Wang, Jian Fang et al. · Journal of Thoracic Oncology · 2020 · 396 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

Jianming Xu, Haiping Jiang, Yueyin Pan et al. · JAMA · 2023 · 357 citations · Full text

Medicine, Oncology, Pharmacology +17

Salivary Transcriptomic Biomarkers for Detection of Resectable Pancreatic Cancer

Lei Zhang, James J. Farrell, Hui Zhou et al. · Gastroenterology · 2009 · 339 citations · Full text

Life Sciences, Molecular Biology, Oncology +14

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Caicun Zhou, Caicun Zhou, Lin Wu et al. · Journal of Thoracic Oncology · 2021 · 317 citations · Full text

Medicine, Oncology, Pharmacology +8